Company
Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Cognigenics

Company Type: Therapeutics

Main focus: Non-viral delivery of CRISPR-based therapeutics to central nervous system

Company stage: Pre-clinical

Diseases: Neurodegenerative disorders

Genome-editing tool: CRISPR-Cas

Funding stage: Seed stage

Location: Idaho, USA

Website: https://www.cognigenics.io/

Pipeline:

Partners:

Cognigenics is a pre-clinical-stage biotech that has developed a method for intranasal adeno-associated virus (AAV)-based delivery of CRISPR-Cas reagents. Cognigenics’ delivery modality allows the gene-editing cargo to pass the blood brain barrier and reach the central nervous system to treat neurodegenerative disorders.

Tags

HashtagCognigenics

Company: Cognigenics
close
Search CRISPR Medicine